ORIC Pharmaceuticals. has filed a patent for compounds inhibiting Polo Like Kinase 4 (PLK4) to treat cancer. The compounds of Formula (I) and their salts are disclosed, along with pharmaceutical compositions and treatment methods. GlobalData’s report on ORIC Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Premium Insights ORIC Pharmaceuticals Inc - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on ORIC Pharmaceuticals, Peptide pharmacophores was a key innovation area identified from patents. ORIC Pharmaceuticals's grant share as of January 2024 was 24%. Grant share is based on the ratio of number of grants to total number of patents.

The patent application (Publication Number: US20230365537A1) discloses a compound selected from a specific group or a pharmaceutically acceptable salt thereof. The claims outline various scenarios where the compound can be in the form of a salt or the compound itself. The patent also includes a pharmaceutical composition containing the compound or its salt along with other pharmaceutically acceptable excipients.

The claims in the patent application emphasize the use of a compound from a defined group or its pharmaceutically acceptable salt in pharmaceutical compositions. The patent aims to protect the specific compound and its variations in salt form for potential therapeutic applications. By detailing the different possibilities of the compound's presentation, the patent provides a broad scope for its utilization in the pharmaceutical industry. The inclusion of pharmaceutically acceptable excipients in the composition further highlights the intention to create a formulation suitable for medical use. Overall, the patent application focuses on the compound's versatility and its potential as a key component in pharmaceutical compositions.

To know more about GlobalData’s detailed insights on ORIC Pharmaceuticals, buy the report here.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies